Pfizer buys stake in liver gene therapy player Vivet
Pfizer Inc has paid 45m upfront to French gene therapy specalist Vivet Therapeutics in a licence option deal for Vivet’s preclinical Wilson disease candidate VTX-801.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1118 entries already.
Entries by Thomas Gabrielczyk
Sotio on track for 2nd Phase III trial
/in News/by Thomas GabrielczykAfter positive preliminary results of Sotio’s SOV02 trial in ovarian cancer had been presented last year, the final analysis confirmed the survival benefits. The Czech biotech company now plans to […]
AMR Conference in Berlin: Call for better incentives
/in News/by Thomas GabrielczykMore than 330 experts joined the 2-day AMR Conference 2019 in Berlin. They called for rapid capital investments and economic incentives in the fight against antimicrobial resistance (AMR).
Biomarker can exclude acute kidney injury
/in News/by Thomas GabrielczykData presented at the 24th AKI & CRRT conference, suggest that the kidney function marker pro-enkephalin (penKid) is capable to rule out acute kidney injury (AKI) with a single measurement.
Researchers target neuroblastoma with ALK-ADC
/in News/by Thomas GabrielczykResearchers at Celldex Therapeutics, Inc and Nerviano Medical Science Srl report elimination of the most common childhood cancer by an ADC in xenografted mice expressing either wild-type or mutated ALK.
AMR: Germany set to invest 39m into CARB-X
/in News/by Thomas GabrielczykGlobal antibacterial innovation network CARB-X announced during an AMR business conference in Berlin that Germany has joined the CARB-X partnership.
AstraZeneca partners with Seres Therapeutics
/in News/by Thomas GabrielczykUnder a three-year agreement, British pharma giant AstraZeneca plc pays 20m and R&D costs to Seres Therapeutics Inc, which will identify patterns in the microbiome predicting therapy response to cancer […]
Small-molecule acts as broad-band influenza entry blocker
/in News/by Thomas GabrielczykResearchers at Janssen Pharmaceutical Companies of Johnson & Johnson in Leiden have developed a small molecule antibody mimic, that prevents entry of multiple influenza virus serotypes.
Seventure starts second microbiome-focussed fund
/in News/by Thomas GabrielczykSeventure Partners has announced the first close of its second microbiome fund designed to put 200m in 20 companies developing microbiome-based health solutions.
EMA approves eight meds for market
/in News/by Thomas GabrielczykThe EMAs human medicines committee (CHMP) has recommended eight medicines for approval in its last meeting in London, two thereof orphan medicines. Three got conditional marketing authorisation.